New productsHealthcare - Pharma - Biotech
Press Release: Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages
19/11/2026 07:00
AMFImmediate publication
Paris, November 19, 2026. Sanofi announced today that the European Commission has approved VaxRabeo (rabies virus inactivated strain Wistar) for pre-exposure prophylaxis (PrEP)
Press Release
Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages
Paris, November 19, 2026. Sanofi announced today that the European Commission has approved VaxRabeo (rabies virus inactivated strain Wistar) for pre-exposure prophylaxis (PrEP)
and post-exposure prophylaxis (PEP) against rabies for all age groups. This is the first marketing authorisation approval for VaxRabeo and follows the positive opinion adopted by the European
Medicines Agency’s Committee for Medicinal Products for Human Use on September 17, 2026.
VaxRabeo is manufactured using state of the art Vero-cell technology. It is formulated to minimize the risk of allergic reactions and has a longer shelf life than current Sanofi rabies vaccines with an improved thermostability.
Rabies is a viral zoonotic disease present in 150 countries, causing approximately 59,000 deaths worldwide annually, according to World Health Organization (WHO) estimates. No treatment exists and it is only preventable by vaccines (in combination with immunoglobulins in postexposure prophylaxis); once clinical symptoms appear, the disease is almost always fatal. It is transmitted primarily through the saliva of infected animals, most commonly via dog bites, and remains a significant global public health challenge despite being entirely vaccine preventable.
According to the WHO, approximately 29 million people receive post-exposure vaccination each year.
"Death from rabies should be prevented at all costs; it is entirely preventable with vaccination provided on time. This first approval of VaxRabeo is a proud milestone for Sanofi and reflects our commitment to rabies protection, built on five decades of expertise and innovation. With VaxRabeo, we are bringing a next-generation rabies vaccine to healthcare systems and patients," said Thomas Triomphe, Head of Vaccines, Sanofi.
The EU approval is supported by a comprehensive clinical programme comparing VaxRabeo with
Sanofi’s current standard of care vaccines (Verorab and Imovax Rabies) in both PrEP and PEP settings, across all age groups and WHO recommended schedules. VaxRabeo showed comparable protective antibody levels in PrEP, a similar immunogenicity profile in PEP, and high boostability of the booster dose given 12 or 24-36 months after PrEP. VaxRabeo showed a safety profile in line with existing vaccines and no significant safety concerns.
About rabies
Rabies is a viral zoonotic disease that affects the central nervous system. Transmission occurs predominantly through the saliva of infected animals, with dogs responsible for most human cases, typically through bites, scratches, and contact with broken skin. Other mammals, including cats, bats, foxes, raccoons, skunks, jackals, and mongooses can also transmit the virus to humans. Children bear a disproportionate burden: 40% of people bitten by suspect rabid animals are under 15 years of age. Despite being entirely vaccine preventable rabies continues to cause preventable deaths, particularly in Asia and Africa. For travellers visiting endemic regions, potential rabies exposure occurs in approximately 0.4% of travellers per month of stay, making pre-travel vaccination an important consideration.